BUZZ-Viking Therapeutics rises on plans to test oral obesity drug in late-stage studies

Reuters

02/12

BUZZ-<a href="https://laohu8.com/S/VKTX">Viking</a> <a href="https://laohu8.com/S/LENZ">Therapeutics</a> rises on plans to test oral obesity drug in late-stage studies

** Shares of obesity drug developer Viking Therapeutics VKTX.O rise 9.4% to $31.24 after hours

** VKTX says it plans to advance its experimental oral obesity drug VK2735 into late-stage trials in Q3 of this year

** "The company believes the availability of both an oral and an injectable formulation is an important factor differentiating VK2735 from competitive agents, as no other dual or triple agonist is currently available in both formulations" — VKTX

** Late-stage study results have shown that once-daily doses of the oral tablet formulation of VK2735 showed up to 12.2% average weight loss after 13 weeks

** VKTX was down 12.6% in 2025

(Reporting by Sneha S K)

((Sneha.SK@thomsonreuters.com))

应版权方要求，你需要登录查看该内容

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2610396413"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2610396413\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2610396413?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-12 06:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2610396413","market":"us","top_or_hot":-1,"title":"BUZZ-Viking Therapeutics rises on plans to test oral obesity drug in late-stage studies","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-<a href=\"https://laohu8.com/S/VKTX\">Viking</a> <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> rises on plans to test oral obesity drug in late-stage studies</title></head><body><p>** Shares of obesity drug developer Viking Therapeutics <span>VKTX.O</span> rise 9.4% to $31.24 after hours </p><p>** VKTX says it plans to advance its experimental oral obesity drug VK2735 into late-stage trials in Q3 of this year </p><p>** \"The company believes the availability of both an oral and an injectable formulation is an important factor differentiating VK2735 from competitive agents, as no other dual or triple agonist is currently available in both formulations\"  — VKTX </p><p> ** Late-stage study results have shown that once-daily doses of the oral tablet formulation of VK2735 showed up to 12.2% average weight loss after 13 weeks</p><p>** VKTX was down 12.6% in 2025  </p><p>(Reporting by Sneha S K)</p><p>((Sneha.SK@thomsonreuters.com))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Viking Therapeutics rises on plans to test oral obesity drug in late-stage studies</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Viking Therapeutics rises on plans to test oral obesity drug in late-stage studies\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-12 06:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-<a href=\"https://laohu8.com/S/VKTX\">Viking</a> <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> rises on plans to test oral obesity drug in late-stage studies</title></head><body><p>** Shares of obesity drug developer Viking Therapeutics <span>VKTX.O</span> rise 9.4% to $31.24 after hours </p><p>** VKTX says it plans to advance its experimental oral obesity drug VK2735 into late-stage trials in Q3 of this year </p><p>** \"The company believes the availability of both an oral and an injectable formulation is an important factor differentiating VK2735 from competitive agents, as no other dual or triple agonist is currently available in both formulations\"  — VKTX </p><p> ** Late-stage study results have shown that once-daily doses of the oral tablet formulation of VK2735 showed up to 12.2% average weight loss after 13 weeks</p><p>** VKTX was down 12.6% in 2025  </p><p>(Reporting by Sneha S K)</p><p>((Sneha.SK@thomsonreuters.com))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VKTX","symbol_name":"Viking Therapeutics, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nL4N3Z7295:1","article_id":"2610396413","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2610396413","pubTimestamp":1770847480,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-Viking Therapeutics rises on plans to test oral obesity drug in late-stage studies** Shares of obesity drug developer Viking Therapeutics VKTX.O rise 9.4% to $31.24 after hours ** VKTX says it plans to advance its experimental oral obesity drug VK2735 into late-stage trials in Q3 of this year ** \"The company believes the availability of both an oral and an injectable formulation is an important factor differentiating VK2735 from competitive agents, as no other dual or triple agonist is currently available in both formulations\"  — VKTX  ** Late-stage study results have shown that once-daily doses of the oral tablet formulation of VK2735 showed up to 12.2% average weight loss after 13 weeks** VKTX was down 12.6% in 2025  ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"VKTX":"Viking Therapeutics, Inc.","BK4599":"减肥药","BK4585":"ETF&股票定投概念","BK4588":"碎股","BK4139":"生物科技"},"translate_title":"BUZZ-Viking Therapeutics计划在后期研究中测试口服肥胖药物","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VKTX":0.9},"content_text":"BUZZ-Viking Therapeutics rises on plans to test oral obesity drug in late-stage studies** Shares of obesity drug developer Viking Therapeutics VKTX.O rise 9.4% to $31.24 after hours ** VKTX says it plans to advance its experimental oral obesity drug VK2735 into late-stage trials in Q3 of this year ** \"The company believes the availability of both an oral and an injectable formulation is an important factor differentiating VK2735 from competitive agents, as no other dual or triple agonist is currently available in both formulations\"  — VKTX  ** Late-stage study results have shown that once-daily doses of the oral tablet formulation of VK2735 showed up to 12.2% average weight loss after 13 weeks** VKTX was down 12.6% in 2025  (Reporting by Sneha S K)((Sneha.SK@thomsonreuters.com))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":true,"code":"91000000","status":"200"}}}